Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Background: Atrial fibrillation (AF), the most common sustained cardiac arrhythmia, increases thromboembolic stroke risk five-fold. Although atrial hypocontractility contributes to stroke risk in AF, the molecular mechanisms reducing myofilament contractile function remain unknown. We tested the hypothesis that increased expression of PPP1R12C, the PP1 regulatory subunit targeting atrial myosin light chain 2 (MLC2a), causes hypophosphorylation of MLC2a and results in atrial hypocontractility.

Methods: Right atrial appendage tissues were isolated from human AF patients versus sinus rhythm (SR) controls. Western blots, co-immunoprecipitation, and phosphorylation studies were performed to examine how the PP1c-PPP1R12C interaction causes MLC2a de-phosphorylation. studies of pharmacologic MRCK inhibitor (BDP5290) in atrial HL-1 cells were performed to evaluate PP1 holoenzyme activity on MLC2a. Cardiac-specific lentiviral PPP1R12C overexpression was performed in mice to evaluate atrial remodeling with atrial cell shortening assays, echocardiography, and AF inducibility with EP studies.

Results: In human patients with AF, PPP1R12C expression was increased two-fold versus SR controls ( =2.0×10 , n=12,12 in each group) with > 40% reduction in MLC2a phosphorylation ( =1.4×10 , n=12,12 in each group). PPP1R12C-PP1c binding and PPP1R12C-MLC2a binding were significantly increased in AF ( =2.9×10 and 6.7×10 respectively, n=8,8 in each group). studies utilizing drug BDP5290, which inhibits T560-PPP1R12C phosphorylation, demonstrated increased PPP1R12C binding with both PP1c and MLC2a, and dephosphorylation of MLC2a. Lenti-12C mice demonstrated a 150% increase in LA size versus controls ( =5.0×10 , n=12,8,12), with reduced atrial strain and atrial ejection fraction. Pacing-induced AF in Lenti-12C mice was significantly higher than controls ( =1.8×10 and 4.1×10 respectively, n= 6,6,5).

Conclusions: AF patients exhibit increased levels of PPP1R12C protein compared to controls. PPP1R12C overexpression in mice increases PP1c targeting to MLC2a and causes MLC2a dephosphorylation, which reduces atrial contractility and increases AF inducibility. These findings suggest that PP1 regulation of sarcomere function at MLC2a is a key determinant of atrial contractility in AF.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10153354PMC
http://dx.doi.org/10.1101/2023.04.19.537590DOI Listing

Publication Analysis

Top Keywords

atrial
14
mlc2a
10
myosin light
8
light chain
8
atrial hypocontractility
8
atrial fibrillation
8
stroke risk
8
human patients
8
ppp1r12c overexpression
8
versus controls
8

Similar Publications

Development and external validation of a clinical prediction model for new-onset atrial fibrillation in intensive care: a multicentre, retrospective cohort study.

Lancet Digit Health

September 2025

Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK; NIHR Biomedical Research Centre, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK; Oxford University Hospitals NHS Foundation Trust, Oxford, UK.

Background: New-onset atrial fibrillation, a condition associated with adverse outcomes in the short and long term, is common in patients admitted to intensive care units (ICUs). Identifying patients at high risk could inform trials of preventive interventions and help to target such interventions. We aimed to develop and externally validate a prediction model for new-onset atrial fibrillation in patients admitted to ICUs.

View Article and Find Full Text PDF

Objective: The impact of off-label underdosing of direct oral anticoagulants (DOACs) on clinical outcomes in patients with atrial fibrillation (AF) and stable coronary artery disease (CAD) remains unclear.

Methods: The EPIC-CAD trial (Edoxaban vs Edoxaban with antiPlatelet agent In patients with atrial fibrillation and Chronic stable Coronary Artery Disease) randomised patients with AF and stable CAD to receive either edoxaban monotherapy or dual antithrombotic therapy (edoxaban plus single antiplatelet agent). Off-label underdosing was defined as low-dose edoxaban (30 mg once daily) without standard criteria for dose reduction.

View Article and Find Full Text PDF

Background: Atrial fibrillation (AF) is the most common arrhythmia in adults, with incidence increasing with age. Cognitive impairment (CoI) and dementia share risk factors with AF. Meta-analyses indicate that AF increases the risk of CoI by 2.

View Article and Find Full Text PDF

Background: Electronic nicotine delivery systems (ENDS) utilize "E-liquids" in order to generate "E-vapor", an inhalable aerosolized mixture containing nicotine and flavors. Flavored ENDS are very popular among teens who vape, however, the possible cardiac electrophysiological harm of inhalation exposure to flavored ENDS are not fully understood.

Objective: To test if inhalation exposure to flavoring carbonyls in e-liquids compromises mitochondrial integrity, increases oxidative stress, and leads to cardiac electrophysiological toxicity.

View Article and Find Full Text PDF